11.4 Nucleotide metabolism and salvage pathways

Nucleotide Biosynthesis Pathways

Nucleotide metabolism provides the building blocks for DNA and RNA. Cells rely on two strategies to maintain their nucleotide pools: building nucleotides from simple precursors (de novo synthesis) or recycling bases and nucleosides from nucleic acid turnover (salvage pathways). Because DNA replication demands a balanced and adequate supply of dNTPs, understanding how these pathways are regulated connects directly to topics like cell proliferation, cancer pharmacology, and inherited metabolic diseases.

De Novo Synthesis

De novo synthesis constructs the purine or pyrimidine ring system step by step from small molecules: amino acids (glycine, glutamine, aspartate), $CO_2$, and tetrahydrofolate (THF) one-carbon donors.

• The ring is assembled on a sugar-phosphate scaffold (for purines) or built as a free base first (for pyrimidines) before attachment to ribose-5-phosphate.
• This is an energy-intensive process that consumes multiple equivalents of ATP and GTP per nucleotide produced.
• De novo synthesis is the dominant route in rapidly dividing cells that need large quantities of new nucleotides.

Salvage Pathways

Salvage pathways recycle preformed nucleobases and nucleosides released during normal nucleic acid and nucleotide turnover.

• Phosphoribosyltransferases attach a ribose-5-phosphate unit (donated by PRPP) directly to a free base, regenerating a nucleoside monophosphate in a single step.
  • HGPRT (hypoxanthine-guanine phosphoribosyltransferase) salvages hypoxanthine → IMP and guanine → GMP.
  • APRT (adenine phosphoribosyltransferase) salvages adenine → AMP.
• Because the ring is already intact, salvage bypasses all the ATP-costly ring-building reactions, making it far more energy-efficient than de novo synthesis.
• Most non-dividing tissues (especially the brain) rely heavily on salvage rather than de novo synthesis.

Key Enzymes in Nucleotide Biosynthesis

Ribonucleotide reductase (RNR) catalyzes the reduction of ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs). This is the only pathway that produces the deoxyribonucleotide precursors needed for DNA synthesis (ultimately yielding dATP, dGTP, dCTP, and dTTP).

• RNR is allosterically regulated at two sites:
  • An activity site that turns the whole enzyme on or off (ATP activates; dATP inhibits).
  • A specificity site that determines which NDP substrate is preferred, ensuring a balanced ratio of all four dNTPs.
• Imbalanced dNTP pools increase replication errors, so this regulation is critical for genomic fidelity.

Nucleoside kinases phosphorylate nucleosides to nucleoside monophosphates, feeding salvaged nucleosides back into the active nucleotide pool. Key examples include thymidine kinase, adenosine kinase, and deoxycytidine kinase. These enzymes are particularly important in the salvage pathway and are also exploited pharmacologically (e.g., thymidine kinase activates certain antiviral prodrugs).

Purine and Pyrimidine Metabolism

Purine Metabolism

Purine de novo synthesis builds the ring directly on phosphoribosyl pyrophosphate (PRPP). The key steps:

1. PRPP amidotransferase commits PRPP to the purine pathway (this is the rate-limiting, regulated step).
2. A series of ~10 reactions assemble the purine ring, incorporating atoms from glycine, glutamine, aspartate, $CO_2$, and $N^{10}$-formyl-THF.
3. The first complete purine nucleotide formed is inosine monophosphate (IMP).
4. IMP sits at a branch point: it is converted to AMP (requires GTP) or GMP (requires ATP). This reciprocal energy requirement helps balance AMP and GMP production.

Purine degradation in humans proceeds as follows:

• Purine nucleotides → nucleosides → free bases (hypoxanthine, xanthine) via purine nucleoside phosphorylase.
• Xanthine oxidase oxidizes hypoxanthine → xanthine → uric acid.
• Humans lack urate oxidase, so uric acid is the final degradation product and is excreted in urine. Many other mammals can further convert uric acid to the more soluble allantoin.

Pyrimidine Metabolism

A major difference from purine synthesis: the pyrimidine ring is built first as a free base, then attached to ribose-5-phosphate.

1. Carbamoyl phosphate synthetase II (cytosolic, distinct from the mitochondrial CPS I of the urea cycle) condenses glutamine + $CO_2$ + ATP → carbamoyl phosphate.
2. Carbamoyl phosphate + aspartate → dihydroorotate → orotate (a key intermediate).
3. Orotate phosphoribosyltransferase attaches orotate to PRPP, forming orotidine-5'-monophosphate (OMP).
4. OMP is decarboxylated to UMP, the parent pyrimidine nucleotide. UMP is then phosphorylated to UTP, and UTP is aminated to CTP.

Pyrimidine degradation differs from purine degradation in that the ring is fully broken open:

• CTP and UTP are degraded to β-alanine.
• dTMP is degraded to β-aminoisobutyrate.
• These products are water-soluble and non-toxic, so pyrimidine degradation does not cause the clinical problems seen with purine degradation.

Salvage enzymes for pyrimidines include orotate phosphoribosyltransferase and uracil phosphoribosyltransferase. 5'-Nucleotidases hydrolyze nucleoside monophosphates back to nucleosides and inorganic phosphate, helping regulate the size of intracellular nucleotide pools.

Disorders of Nucleotide Metabolism

Hyperuricemia and Gout

Because humans cannot degrade uric acid further, excess purine turnover or impaired renal excretion leads to hyperuricemia (serum uric acid > 6.8 mg/dL). When uric acid exceeds its solubility limit, monosodium urate crystals deposit in joints and soft tissues.

• These crystals trigger an intense inflammatory response, producing the acute pain, redness, and swelling of gout (classically affecting the first metatarsophalangeal joint).
• Risk factors: genetics, high-purine diet (red meat, organ meats, seafood), alcohol (especially beer), obesity, and certain medications (thiazide diuretics, cyclosporine).

Other Disorders of Nucleotide Metabolism

Lesch-Nyhan syndrome is a rare X-linked recessive disorder caused by near-complete deficiency of HGPRT.

• Without HGPRT, the purine salvage pathway is non-functional. Free hypoxanthine and guanine cannot be recycled, so they are instead degraded to uric acid, causing severe hyperuricemia.
• PRPP that would normally be consumed by HGPRT accumulates, driving increased de novo purine synthesis and further uric acid overproduction.
• Clinical features include gout, kidney stones, neurological dysfunction (dystonia, spasticity), intellectual disability, and characteristic compulsive self-injurious behavior. The neurological symptoms highlight how dependent the brain is on the purine salvage pathway.

Orotic aciduria is a rare autosomal recessive disorder caused by deficiency of UMP synthase (a bifunctional enzyme with orotate phosphoribosyltransferase and OMP decarboxylase activities).

• Pyrimidine de novo synthesis stalls at orotate, which accumulates and is excreted in the urine.
• Patients present with megaloblastic anemia (impaired DNA synthesis in rapidly dividing blood cell precursors) and growth retardation.
• Treatment: oral uridine supplementation bypasses the enzymatic block and restores pyrimidine nucleotide levels. Importantly, orotic aciduria does not respond to vitamin $B_{12}$ or folate, which distinguishes it from other causes of megaloblastic anemia.